Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pharma Mar SA ( (ES:PHM) ) has shared an update.
Pharma Mar SA announced positive results from the phase 3 IMforte study, showcasing the effectiveness of Zepzelca® (lurbinectedin) combined with atezolizumab as a first-line maintenance treatment for advanced-stage small cell lung cancer (SCLC). The study demonstrated significant improvements in progression-free and overall survival, marking a potential new standard in SCLC treatment. The results were presented at the ASCO meeting and published in The Lancet, with a marketing authorization application submitted to the European Medicines Agency.
The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.
More about Pharma Mar SA
Pharma Mar SA is a biopharmaceutical company focused on oncology, developing innovative drugs for cancer treatment. The company specializes in marine-derived drugs and has a significant presence in the global oncology market.
Average Trading Volume: 58,388
Technical Sentiment Signal: Strong Buy
Current Market Cap: €1.59B
See more data about PHM stock on TipRanks’ Stock Analysis page.